Contact
searchSearch
HMP Global
Login

Glioma

Glioma
Specialty Channel
News
Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma
07/21/2026
Emily Estrada
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase...
07/21/2026
Oncology
News
Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma
07/09/2026
Stephanie Holland
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial...
07/09/2026
Oncology
News
Radiotherapy and Temozolomide Produce Comparable Long-Term Outcomes in High-Risk Low-Grade Glioma
07/07/2026
Stephanie Holland
Long-term follow-up of a phase 3 trial showed that initial treatment with either radiotherapy or dose-dense temozolomide produced comparable survival outcomes in patients with clinically high-risk low-grade glioma, while molecular...
Long-term follow-up of a phase 3 trial showed that initial treatment with either radiotherapy or dose-dense temozolomide produced comparable survival outcomes in patients with clinically high-risk low-grade glioma, while molecular...
Long-term follow-up of a phase 3...
07/07/2026
Oncology
News
MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma
06/30/2026
Emily Estrada
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED...
06/30/2026
Oncology
News
WT1 Peptide Vaccine Demonstrates Immune Activity in Pediatric High-Grade Gliomas
06/30/2026
Emily Estrada
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study...
06/30/2026
Oncology
News
Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma
06/05/2026
Emily Estrada
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study...
06/05/2026
Oncology
News
ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
06/05/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial...
06/05/2026
Oncology
Quiz
Immune Signatures of Survival in High-Grade Glioma
05/01/2026
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational...
05/01/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology
Quiz
Auceliciclib for Advanced Solid Tumors and Recurrent High-Grade Glioma
03/31/2026
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate...
03/31/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology

News

News
Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma
07/21/2026
Emily Estrada
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase...
07/21/2026
Oncology
News
Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma
07/09/2026
Stephanie Holland
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial...
07/09/2026
Oncology
News
Radiotherapy and Temozolomide Produce Comparable Long-Term Outcomes in High-Risk Low-Grade Glioma
07/07/2026
Stephanie Holland
Long-term follow-up of a phase 3 trial showed that initial treatment with either radiotherapy or dose-dense temozolomide produced comparable survival outcomes in patients with clinically high-risk low-grade glioma, while molecular...
Long-term follow-up of a phase 3 trial showed that initial treatment with either radiotherapy or dose-dense temozolomide produced comparable survival outcomes in patients with clinically high-risk low-grade glioma, while molecular...
Long-term follow-up of a phase 3...
07/07/2026
Oncology
News
MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma
06/30/2026
Emily Estrada
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED...
06/30/2026
Oncology
News
WT1 Peptide Vaccine Demonstrates Immune Activity in Pediatric High-Grade Gliomas
06/30/2026
Emily Estrada
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study...
06/30/2026
Oncology
News
Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma
06/05/2026
Emily Estrada
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study...
06/05/2026
Oncology
News
ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
06/05/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial...
06/05/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology

Interactive Features

Quiz
Immune Signatures of Survival in High-Grade Glioma
05/01/2026
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational...
05/01/2026
Oncology
Quiz
Auceliciclib for Advanced Solid Tumors and Recurrent High-Grade Glioma
03/31/2026
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate...
03/31/2026
Oncology
Quiz
Safusidenib Erbumine for IDH1-Mutated Glioma
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
Evaluating Targeted Therapies in Glioblastoma
01/26/2026
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or false: Targeted...
01/26/2026
Oncology
Quiz
Eflornithine Plus Lomustine for Recurrent Grade 3 Astrocytoma
01/13/2026
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine...
01/13/2026
Oncology
Quiz
Vorasidenib for Previously Untreated Patients With Residual or Recurrent Grade 2 IDH-Mutant Glioma
08/19/2025
The phase 3 INDIGO trial enrolled previously untreated patients with residual or recurrent grade 2 IDH-mutant glioma to receive either vorasidenib or placebo. Which of the following statements best summarizes the primary clinical outcome of...
The phase 3 INDIGO trial enrolled previously untreated patients with residual or recurrent grade 2 IDH-mutant glioma to receive either vorasidenib or placebo. Which of the following statements best summarizes the primary clinical outcome of...
The phase 3 INDIGO trial...
08/19/2025
Oncology
Quiz
Concurrent Temozolomide and Radiotherapy for Patients With Non-Codeleted Anaplastic Glioma
07/28/2025
True or False: Concurrent temozolomide and radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients with non-codeleted anaplastic glioma.
True or False: Concurrent temozolomide and radiotherapy did not improve survival results compared to adjuvant temozolomide plus radiotherapy among patients with non-codeleted anaplastic glioma.
True or False: Concurrent...
07/28/2025
Oncology

Recent News

News
Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma
07/21/2026
Emily Estrada
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...
Updated findings from the phase...
07/21/2026
Oncology
News
Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma
07/09/2026
Stephanie Holland
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial...
07/09/2026
Oncology
News
Radiotherapy and Temozolomide Produce Comparable Long-Term Outcomes in High-Risk Low-Grade Glioma
07/07/2026
Stephanie Holland
Long-term follow-up of a phase 3 trial showed that initial treatment with either radiotherapy or dose-dense temozolomide produced comparable survival outcomes in patients with clinically high-risk low-grade glioma, while molecular...
Long-term follow-up of a phase 3 trial showed that initial treatment with either radiotherapy or dose-dense temozolomide produced comparable survival outcomes in patients with clinically high-risk low-grade glioma, while molecular...
Long-term follow-up of a phase 3...
07/07/2026
Oncology
News
MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma
06/30/2026
Emily Estrada
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED...
06/30/2026
Oncology
News
WT1 Peptide Vaccine Demonstrates Immune Activity in Pediatric High-Grade Gliomas
06/30/2026
Emily Estrada
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study...
06/30/2026
Oncology
News
Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma
06/05/2026
Emily Estrada
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study...
06/05/2026
Oncology
News
ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
06/05/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial...
06/05/2026
Oncology
News
HSK42360 Shows Clinical Promise in BRAF V600-Mutant Glioma
04/29/2026
Emily Estrada
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study demonstrate that HSK42360 shows promising clinical activity with favorable safety in patients with BRAF V600-mutant gliomas.
Results from a phase 1 study...
04/29/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology
FDA Approval
FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases
08/04/2026
Stephanie Holland
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...
The FDA has approved a rituximab...
08/04/2026
Oncology
FDA Alerts
FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote
07/31/2026
Stephanie Holland
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...
The FDA's Cellular, Tissue, and...
07/31/2026
Oncology
FDA Alerts
Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/30/2026
Emily Estrada
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.
The FDA granted Priority Review...
07/30/2026
Oncology
News
Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...
The phase 2 RegoMel trial...
07/29/2026
Oncology
News
Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma
07/29/2026
Stephanie Holland
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...
The phase 2 MONETTE trial found...
07/29/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
News
Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/28/2026
Stephanie Holland
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...
Results from the largest...
07/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use